NASDAQ:JAZZ
Jazz Pharmaceuticals Plc Stock Earnings Reports
$108.07
+0.255 (+0.237%)
At Close: May 23, 2025
Jazz Pharmaceuticals plc Earnings Calls
Q1 2025
Missed
$1.68 (-62.75%)
Release date | May 06, 2025 |
EPS estimate | $4.51 |
EPS actual | $1.68 |
EPS Surprise | -62.75% |
Revenue estimate | 1.065B |
Revenue actual | 897.841M |
Revenue Surprise | -15.68% |
Q4 2024
Beat
$6.60 (13.21%)
Release date | Feb 25, 2025 |
EPS estimate | $5.83 |
EPS actual | $6.60 |
EPS Surprise | 13.21% |
Revenue estimate | 984.985M |
Revenue actual | 1.088B |
Revenue Surprise | 10.48% |
Q3 2024
Beat
$6.61 (20.84%)
Release date | Nov 06, 2024 |
EPS estimate | $5.47 |
EPS actual | $6.61 |
EPS Surprise | 20.84% |
Revenue estimate | 1.057B |
Revenue actual | 1.055B |
Revenue Surprise | -0.184% |
Q2 2024
Beat
$5.30 (13.25%)
Release date | Jul 31, 2024 |
EPS estimate | $4.68 |
EPS actual | $5.30 |
EPS Surprise | 13.25% |
Revenue estimate | 1.038B |
Revenue actual | 1.024B |
Revenue Surprise | -1.34% |
Last 4 Quarters for Jazz Pharmaceuticals plc
Below you can see how JAZZ performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
Release date | Jul 31, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $110.25 |
EPS estimate | $4.68 |
EPS actual | $5.30 |
EPS surprise | 13.25% |
Date | Price |
---|---|
Jul 25, 2024 | $109.54 |
Jul 26, 2024 | $111.57 |
Jul 29, 2024 | $111.11 |
Jul 30, 2024 | $112.27 |
Jul 31, 2024 | $110.25 |
Aug 01, 2024 | $114.38 |
Aug 02, 2024 | $113.26 |
Aug 05, 2024 | $111.60 |
Aug 06, 2024 | $111.37 |
4 days before | 0.648% |
4 days after | 1.02% |
On release day | 3.75% |
Change in period | 1.67% |
Q3 2024
Beat
Release date | Nov 06, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $111.55 |
EPS estimate | $5.47 |
EPS actual | $6.61 |
EPS surprise | 20.84% |
Date | Price |
---|---|
Oct 31, 2024 | $110.03 |
Nov 01, 2024 | $110.45 |
Nov 04, 2024 | $109.41 |
Nov 05, 2024 | $111.43 |
Nov 06, 2024 | $111.55 |
Nov 07, 2024 | $119.08 |
Nov 08, 2024 | $123.61 |
Nov 11, 2024 | $127.12 |
Nov 12, 2024 | $127.74 |
4 days before | 1.38% |
4 days after | 14.51% |
On release day | 6.75% |
Change in period | 16.10% |
Q4 2024
Beat
Release date | Feb 25, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $139.67 |
EPS estimate | $5.83 |
EPS actual | $6.60 |
EPS surprise | 13.21% |
Date | Price |
---|---|
Feb 19, 2025 | $134.96 |
Feb 20, 2025 | $136.65 |
Feb 21, 2025 | $136.01 |
Feb 24, 2025 | $136.69 |
Feb 25, 2025 | $139.67 |
Feb 26, 2025 | $144.17 |
Feb 27, 2025 | $143.27 |
Feb 28, 2025 | $143.53 |
Mar 03, 2025 | $140.22 |
4 days before | 3.49% |
4 days after | 0.394% |
On release day | 3.22% |
Change in period | 3.90% |
Q1 2025
Missed
Release date | May 06, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $111.17 |
EPS estimate | $4.51 |
EPS actual | $1.68 |
EPS surprise | -62.75% |
Date | Price |
---|---|
Apr 30, 2025 | $116.96 |
May 01, 2025 | $117.18 |
May 02, 2025 | $120.05 |
May 05, 2025 | $118.19 |
May 06, 2025 | $111.17 |
May 07, 2025 | $101.44 |
May 08, 2025 | $98.41 |
May 09, 2025 | $97.78 |
May 12, 2025 | $103.58 |
4 days before | -4.95% |
4 days after | -6.83% |
On release day | -8.75% |
Change in period | -11.44% |
Jazz Pharmaceuticals plc Earnings Call Transcript Summary of Q1 2025
Jazz Pharmaceuticals Q1 2025 Earnings Call Summary
Key Highlights for Investors:
- Strong Financial Performance:
- Total revenues for Q1 2025 were $898 million, reflecting strong sales in the neuroscience segment, particularly for Xywav (up 9%) and Epidiolex (up 10%).
- The company acknowledged challenges in their oncology portfolio and a decline in some oncology product revenues compared to the previous year.
- Product Performance:
- Neuroscience Portfolio:
- Xywav remains the number one branded treatment for narcolepsy and the only therapy approved for idiopathic hypersomnia. The current number of active Xywav patients has increased to approximately 14,600.
- Epidiolex showed strong demand and growth amid expanding patient access and ongoing education efforts.
- Oncology Products:
- Zepzelca submitted a supplemental application for expanded use in extensive-stage small cell lung cancer. Anticipated data presentation at ASCO in June could be transformative.
- Positive opinion received from the CHMP for zanidatamab in advanced HER2-positive biliary tract cancer.
- Neuroscience Portfolio:
- Research & Development Pipeline:
- Multiple regulatory milestones expected in 2025, including the pivotal readout of GEA (Gastroesophageal Adenocarcinoma) trial results and PDUFA date for Dordaviprone set for August 18, 2025.
- Strong emphasis on upcoming data at ASCO and ongoing trials for zanidatamab.
- Acquisition of Chimerix:
- The recent acquisition was highlighted as a strategic move to bolster Jazz’s oncology portfolio, specifically for bringing Dordaviprone to market, enhancing their position in rare oncology.
- Updated Financial Guidance:
- 2025 revenue guidance reaffirmed at $4.15 billion to $4.4 billion (approximately 5% year-over-year growth).
- Adjusted net income expected to be in the range of $250 million to $350 million, impacted by legal settlements and the Chimerix acquisition.
- Market Dynamics and Competitive Landscape:
- Continued focus on addressing competition, particularly for Zepzelca and Rylaze. Expectations for normalization and growth with strategic efforts in the AYA (adolescent and young adult) market for Rylaze.
- Tariff impacts are currently managed through inventory strategies, and no significant disruptions are anticipated for 2025.
- Overall Strategy:
- Jazz remains committed to executing their operational excellence strategy while navigating challenges in the dynamic healthcare landscape. Continued investment in R&D and corporate development is a priority.
Conclusion:
Jazz Pharmaceuticals is positioned for growth with strong performances in its neuroscience portfolio and several regulatory milestones ahead. While facing challenges in oncology, strategic acquisitions and an advancing pipeline present a compelling investment narrative for shareholders.
Jazz Pharmaceuticals plc Earnings History
Earnings Calendar
FAQ
When is the earnings report for JAZZ?
Jazz Pharmaceuticals plc (JAZZ) has scheduled its earnings report for Jul 30, 2025 after the markets close.
What is the JAZZ price-to-earnings (P/E) ratio?
JAZZ P/E ratio as of May 23, 2025 (TTM) is 13.69.
What is the JAZZ EPS forecast?
The forecasted EPS (Earnings Per Share) for Jazz Pharmaceuticals plc (JAZZ) for the first fiscal quarter 2025 is -$5.35.
What are Jazz Pharmaceuticals plc's retained earnings?
On its balance sheet, Jazz Pharmaceuticals plc reported retained earnings of $897.84 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.